Method for analyzing fructus evodiae antihypertensive target based on network pharmacology
The method systematically analyzes Evodia rutaecarpa's antihypertensive targets using network pharmacology, identifying key components with strong binding activity on specific proteins, enhancing hypertension treatment efficacy.
Patent Information
- Application Number
- CN202411123855.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-12-03
AI Technical Summary
The key effective ingredients of Evodia rutaecarpa for treating hypertension have not been systematically analyzed, limiting the development of precise and personalized treatment plans.
A method based on network pharmacology is employed to analyze the antihypertensive targets of Evodia rutaecarpa, involving screening of bioactive ingredients, collection of target genes, construction of compound-gene-disease networks, and verification of core targets through molecular docking technology.
Identifies key components like 2-hexyloctanol, dihydroasabuciclovir, evodia rutaecarpine, isorhamnetin, and evodia rutaecarpamide as having the best therapeutic effect on hypertension by acting on proteins such as SRC, MAPK3, STAT3, MAPK1, PIK3R1, AKT1, PIK3CA, RAC1, EGFR, and ESR1, affecting calcium and cancer signaling pathways.
Smart Images

Figure CN119068979A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of drug treatment target analysis, and specifically relates to a method for analyzing blood pressure-lowering targets of Evodia rutaecarpa based on network pharmacology. Background Art
[0002] Hypertension (HTN) is a common chronic disease that can lead to many cardiovascular complications. Since most hypertensive patients have no obvious symptoms, hypertension is also known as the "silent killer". Many Western countries have established a precise, personalized or customized medical framework for the treatment of hypertension. However, according to traditional Chinese medicine treatment theory, hypertension is not recorded separately, but is classified as a clinical symptom such as headache and dizziness. However, Chinese medicine plays an indispensable role in the treatment of hypertension. With the deepening of research, more and more Chinese medicines have been found to have significant therapeutic effects on the treatment of hypertension. Taking Evodiae Fructus (EF) as an example, its key active ingredients such as lutongine can inhibit the increase in blood pressure and arterial hypertrophy in rats with renovascular hypertension, while quercetin can regulate blood pressure to treat hypertensive diseases. However, the key active ingredients of Evodiae Fructus for the treatment of hypertension have not been systematically analyzed. Therefore, it is of great significance to explore and evaluate the targets of Evodiae Fructus fruit in the treatment of hypertension to improve the treatment of hypertension and provide a basis for further research. Summary of the invention
[0003] In order to solve the technical problem that the key effective ingredients of Evodia rutaecarpa in treating hypertension have not been systematically analyzed, the present invention explores and evaluates the targets of Evodia rutaecarpa fruit in the treatment of hypertension based on network pharmacology, which is of great significance for improving the treatment plan for hypertension.
[0004] In order to solve the above technical problems and achieve corresponding technical effects, the present invention specifically provides the following technical solutions:
[0005] The first object of the present invention is to provide a method for analyzing the antihypertensive target of Evodia rutaecarpa based on network pharmacology, which specifically comprises the following steps:
[0006] S1. Screening of blood pressure-lowering bioactive ingredients of Evodia rutaecarpa: All chemical components of Evodia rutaecarpa were obtained from the HERB database and the TCMSP database. Based on the absorption, distribution, metabolism and excretion of pharmacological substances, the SwissADME database was used to screen the blood pressure-lowering bioactive ingredients of Evodia rutaecarpa from the HERB database, and the two standards of OB ≥ 30% and Druglikeness ≥ 0.18 were used to screen the blood pressure-lowering bioactive ingredients of Evodia rutaecarpa in the TCMSP database.
[0007] S2. Collection of target genes of Evodia rutaecarpa for treating hypertension: Obtain the SMILES names corresponding to the blood pressure-lowering bioactive components of Evodia rutaecarpa screened from the HERB database and the TCMSP database in S1, and bring them into the SwissTargetPrediction database to obtain the target genes of Evodia rutaecarpa for treating hypertension;
[0008] S3. Determine the target genes of Evodia rutaecarpa for treating hypertension based on the target genes of hypertension: Obtain the target genes of hypertension using the GeneCards database and the DisGeNET database, and draw a Venn diagram of the target genes of hypertension and the target genes of Evodia rutaecarpa for treating hypertension described in S2 using the online tool Venny 2.1. The common genes are the target genes of Evodia rutaecarpa for treating hypertension.
[0009] S4. Construction of compound-gene-disease network: Cytoscape3.9.1 software was used to generate a compound-gene-disease network diagram reflecting the relationship between the blood pressure-lowering bioactive components of Evodia rutaecarpa obtained in S1 and the target genes for treating hypertension of Evodia rutaecarpa obtained in S3;
[0010] S5. Construct protein interaction network and extract core targets: Import the target genes of Evodia rutaecarpa for the treatment of hypertension obtained in S3 into the online tool STRING, then select "Homo sapiens", set the minimum required interaction score to a high value ≥ 0.9, hide idle nodes, and select the number of kmeans clusters as 3 in Cluster Option to obtain the protein interaction network and export the corresponding files. Upload the files to Cytoscape3.9.1 software and use the cytoNCA plug-in in the software to extract core targets.
[0011] In one embodiment of the present invention, S1 is a method for screening blood pressure lowering bioactive ingredients of Evodia rutaecarpa from the HERB database, which is to screen ingredients that meet Lipinski's five rules: Mw≤500, miLogP≤5, nOHNH≤5, nOH≤10, the sum of the "Yes" numbers of Lipinsk, Ghose, Veber, Egan and Muegge is greater than 2, and the bioavailability is ≥30%, the oral bioavailability (OB) is ≥30%, and the GI absorption tendency is "high".
[0012] In one embodiment of the present invention, S2 is a method for collecting target genes of Evodia rutaecarpa for treating hypertension from the HERB database, which is to use the PubChem database to detect the blood pressure-lowering bioactive component genes of Evodia rutaecarpa screened from the HERB database, find their SMILES names, and then bring them into the SwissTargetPrediction database to obtain the target genes of Evodia rutaecarpa for treating hypertension.
[0013] In one embodiment of the present invention, S2 is a method for collecting target genes of Evodia rutaecarpa for treating hypertension from the TCMSP database, which is to screen out active ingredients in Evodia rutaecarpa with therapeutic effects on hypertension from the TCMSP database, that is, have SMILES names, and directly bring the SMILES names into the SwissTargetPrediction database to obtain target genes of Evodia rutaecarpa for treating hypertension.
[0014] In one embodiment of the present invention, after obtaining the antihypertensive target of Evodia rutaecarpa, in order to further prove the role of Evodia rutaecarpa in treating hypertension, the DAVID database (https: / / david.ncifcrf.gov) was used to perform GO functional enrichment and KEGG enrichment analysis on the target genes of Evodia rutaecarpa in treating hypertension in terms of biological process (BP), cellular component (CC), and molecular function (MF). The 292 target genes of Evodia rutaecarpa in treating hypertension obtained were imported into the database for research preview, and the species was designated as "Homo sapiens". The exported results were visualized by the online mapping tool Microinformatics (http: / / www.bioinformatics.com.cn / ), and the "disease-pathway-target-component drug" network was constructed using Cytoscape3.9.1.
[0015] In one embodiment of the present invention, after obtaining the antihypertensive target of Evodia rutaecarpa, in order to further prove the role of Evodia rutaecarpa in treating hypertension, the strong binding activity of the main components and the core targets was verified by molecular docking technology, and the binding sites were constructed to evaluate the active space. The specific method is that in the CGD network, the cytoNCAplugins tool in the Cytoscape3.9.1 software can screen out the five most important components according to the degree value. Then the PPI network is used to build the network, and five critical gene targets are screened out according to the size of the degree value. The core protein structures of the above five gene targets are obtained from the PDB online database (https: / / www.rcsb.org). After that, low-resolution X-ray structures, human structures, and structures of nucleotide binding sites binding ligands are preferentially selected. At the same time, these five compounds need to be formatted so that they can be used in subsequent software. The SDF format of the 3D structure is obtained from the PubChem database and converted to MOL2 format using OpenBable2.4.1 software. PyMol2.5.0 software, installed by open source tools Python2.7, Miniconda3, Numpy1.19.5 and Pmw2.0.1, is often used to remove water and ligands and measure the distance between docked ligands and proteins. Afterwards, AutoDock4 and AutoDockTool4
[0016] (https: / / autodock.scripps.edu) to dock the protein and ligand and calculate the binding energy. The exported files are in PDBQT format and need to be converted to PDB format. They are then used in PyMol2.5.0 to measure distances and visualize the docking map of the protein and ligand. The binding site is constructed in PyMol2.5.0 software.
[0017] The second object of the present invention is to provide a computer device, which includes a memory, a processor, and a computer program stored in the memory and executable on the processor, wherein the processor implements the above-mentioned method for analyzing the antihypertensive targets of Evodia rutaecarpa based on network pharmacology when executing the computer program.
[0018] The third object of the present invention is to provide a computer-readable storage medium having a computer program stored thereon, and when the computer program is executed by a processor, the method for analyzing the antihypertensive targets of Evodia rutaecarpa based on network pharmacology is implemented.
[0019] Beneficial effects of the present invention:
[0020] The present invention explores and evaluates the target of Evodia rutaecarpa fruit in the treatment of hypertension. From the perspective of network pharmacology, the relationship between Evodia rutaecarpa and hypertension in multi-compound, multi-target and multi-pathway treatment is systematically described, and the strong binding activity of the main components with the core targets is verified by molecular docking technology, and the binding sites are constructed to evaluate the active space. The results show that the five main components of Evodia rutaecarpa, 2-hexyloctanol, dihydroasabuciclovir, evodia rutaecarpine, isorhamnetin and evodia rutaecarpamide, have the best therapeutic effect on hypertension, acting on 10 major proteins such as SRC, MAPK3, STAT3, MAPK1, PIK3R1, AKT1, PIK3CA, RAC1, EGFR, ESR1, etc., affecting calcium signaling pathways, cancer signaling pathways, sphingolipid signaling pathways, cAMP signaling pathways, etc. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 It is a Venn diagram of the intersection of the target genes of the bioactive ingredients in Evodia rutaecarpa that have therapeutic effects on hypertension and the target genes of hypertension diseases; among them, EF is the target gene of the bioactive ingredients in Evodia rutaecarpa that have therapeutic effects on hypertension, and Hypertension is the target gene of hypertension diseases;
[0022] Figure 2 This is a CGD network diagram reflecting the relationship between the blood pressure-lowering bioactive components of Evodia rutaecarpa and the target genes of Evodia rutaecarpa in treating hypertension; among them, Wu1, Wu2, Wu3, ... Wu-38 represent the active components of Evodia rutaecarpa;
[0023] Figure 3 This is the PPI network diagram of target genes for the treatment of hypertension by Evodia rutaecarpa; Figure 3 The balls of different colors represent clusters of different genes;
[0024] Figure 4 This is the network diagram of the ten core targets of Evodia rutaecarpa acting on hypertension;
[0025] Figure 5 This is the result diagram of biological process enrichment analysis of target genes of Evodia rutaecarpa in treating hypertension;
[0026] Figure 6 This is the result of the cellular component enrichment analysis of target genes of Evodia rutaecarpa in treating hypertension;
[0027] Figure 7 This is the result of molecular function enrichment analysis of target genes of Evodia rutaecarpa in treating hypertension;
[0028] Figure 8 The result diagram of 20 top pathways obtained by KEGG enrichment analysis of target genes of Evodia rutaecarpa in treating hypertension;
[0029] Fig. 9 The disease-pathway-target-ingredient drug network diagram of Evodia rutaecarpa acting on hypertension;
[0030] Fig.10 This is a visualization result diagram of the molecular docking between protein and ligand; Fig.10 (AI) in the figure is the visualization result of molecular docking between PIK3R1 protein and Rutaecarpine ligand. Fig.10 (AII) in the figure is an enlarged view of (AI). Fig.10 (BI) in the figure is the visualization result of molecular docking between MAPK3 protein and Rutaecarpine ligand. Fig.10 (BII) in the figure is an enlarged view of (BI). Fig.10 (CI) in the figure is the visualization result of molecular docking between PIK3R1 protein and Evodiamide ligand. Fig.10 (CII) in the figure is an enlarged view of (CI). Fig.10 (DI) in the figure is the visualization result of molecular docking between PIK3R1 protein and Isorhamnetin ligand. Fig.10 (DII) in the figure is an enlarged view of (DI);
[0031] Fig.11 is the binding activity diagram of protein and ligand; Fig.11 (a) is the binding activity diagram of PIK3R1 protein and Evodiamide ligand. Fig.11(b) is the binding activity diagram of PIK3R1 protein and Isorhamnetin ligand. Fig.11 (c) is the binding activity diagram of PIK3R1 protein and Rutaecarpine ligand. Fig.11 (d) in the figure is the binding activity diagram of MAPK3 protein and Rutaecarpine ligand. DETAILED DESCRIPTION
[0032] The present invention is further described in detail below in conjunction with specific examples and drawings. The following examples are convenient for better understanding of the present invention, but are not intended to limit the present invention. The experimental methods in the following examples are conventional methods unless otherwise specified. The drugs, reagents, and materials used in the following examples can be purchased through commercial channels unless otherwise specified.
[0033] Example 1: A method for analyzing the antihypertensive targets of Evodia rutaecarpa based on network pharmacology
[0034] (1) Screening of blood pressure-lowering bioactive components of Evodia rutaecarpa
[0035] All chemical components in Evodia rutaecarpa were retrieved through the HERB database (http: / / drug.ac.cn / ) and the TCMSP database (http:old.tcmsp-e.com). The blood pressure lowering bioactive components of Evodia rutaecarpa were screened from the HERB database. According to the absorption, distribution, metabolism and excretion (ADME) of pharmacological substances, the SwissADME database (www.swissadme.ch) was used to screen the components that met the Lipinski five rules (Mw≤500, miLogP≤5, nOHNH≤5, nOH≤10), the sum of the "Yes" numbers of Lipinsk, Ghose, Veber, Egan and Muegge was greater than 2, and the bioavailability was ≥30%, the oral bioavailability (OB) was ≥30%, and the GI absorption tendency was "high". At the same time, the blood pressure lowering bioactive components of Evodia rutaecarpa were screened in the TCMSP database with the two standards of OB≥30% and Druglikeness (DL)≥0.18.
[0036] The present invention is based on the HERB database, and a total of 49258 active compounds in Evodia rutaecarpa are obtained. Then, according to the Lipinski five rules, the sum of the "Yes" numbers of Lipinski, Ghose, Veber, Egan and Muegge is greater than 2, and the bioavailability is ≥30%, the oral bioavailability (OB) is ≥30%, and the GI absorption is selected as "high", and 20 active ingredients with the effect of treating hypertension are obtained, including furandione, quinoline, etc. (see Table 1). In addition, the present invention screens out 18 active ingredients with the effect of treating hypertension in Evodia rutaecarpa according to OB≥30% and DL≥0.18 in the TCMSP database (see Table 2). Therefore, a total of 38 active compounds with the effect of treating hypertension are collected in Evodia rutaecarpa for subsequent research.
[0037] Table 1 Bioactive components in Evodia rutaecarpa with therapeutic effects on hypertension screened from the HERB database
[0038]
[0039]
[0040] Table 2 Bioactive components in Evodia rutaecarpa with therapeutic effects on hypertension screened from the TCMSP database
[0041]
[0042] (2) Collection of target genes for the treatment of hypertension with Evodia rutaecarpa
[0043] The PubChem database (https: / / pubchem.ncbi.nlm.nih.gov) was used to detect the genes of active ingredients in Evodia rutaecarpa with therapeutic effects on hypertension screened from the HERB database, and their SMILES names were found. Then, according to the SwissTargetPrediction database (http: / / swisstargetprediction<http: / / swisstargetprediction.ch / > .ch), and obtain the standardized gene names of the corresponding active ingredients. The active ingredients in Evodia rutaecarpa with the effect of treating hypertension screened from the TCMSP database have SMILES names, so they can be directly brought into the SwissTargetPrediction database to obtain standardized gene names. Finally, 716 drug target genes corresponding to 38 active ingredients with the effect of treating hypertension were obtained from the SwissTargetPrediction database.
[0044] (3) Determine target genes for treating hypertension based on target genes of hypertension diseases
[0045] In order to collect more comprehensive target genes, the GeneCards database (https: / / www.genecards.org / ) and the DisGeNET database (http: / / www.disgenet.org / ) were used to search for the keyword "Hypertension" to obtain target genes for hypertension. The GeneCards database can provide comprehensive and detailed information on known human genes, gene expression, and predicted unknown human genes. The DisGeNET database is one of the largest gene databases in the world, covering the entire field of human diseases such as Mendelian diseases, complex diseases, environmental diseases, and genetic diseases, and is used to explain the genetic causes of diseases. Then, the online tool Venny 2.1 (http: / / bioinfogp.cnb.csic.es / tools / venny / ) was used to draw a Venn diagram of the target genes for hypertension and the 716 drug target genes obtained in step (2). The common genes are the potential targets of Evodia rutaecarpa in the treatment of hypertension.
[0046] Based on the GeneCards database and the DisGeNET database, target genes for hypertension were obtained. After the number of genes was normalized and the number of genes was limited to between 1000 and 1500 using Excel Medina, a total of 1957 genes related to hypertension were relatively effective. Subsequently, the Venny online tool was used to draw a Venn diagram, and the 716 drug target genes and 1957 disease genes obtained in step (2) were inserted into it to generate 292 common genes, that is, the target genes of Evodia rutaecarpa for the treatment of hypertension were obtained (see Figure 1 ).
[0047] (4) Construction of compound-gene-disease (CGD) network
[0048] The 38 compounds shown in Table 1 and Table 2 and the target genes of Evodia rutaecarpa for treating hypertension obtained in step (3) were obtained, and the CGD network diagram was prepared using Cytoscape 3.9.1 (https: / / cytoscape.org) software. The network diagram was analyzed and visualized to reflect the relationship between the compound and the disease. There are many interconnected nodes and edges in the network diagram, where "nodes" are used to act as traditional Chinese medicines, ingredients or target genes, and "edges" are used to act as the relationship between nodes.
[0049] The 292 common genes were obtained using the Venny tool, and the components of Evodia rutaecarpa (38 compounds) were obtained using Cytoscape 3.9.1 software to obtain a network diagram (see Figure 2 ). Figure 2There are 331 nodes and 1282 edges in the network diagram shown, in which red nodes, white nodes and blue nodes represent the Chinese medicine Evodia rutaecarpa, effective compounds and overlapping genes, respectively. Among them, the 38 top active compounds listed in Tables 1 and 2 can be expressed, and 292 common genes are dyed blue and connected to each other according to the point-edge relationship.
[0050] (5) Construct protein-protein interaction (PPI) network and extract core targets
[0051] For the PPI network, the 292 target genes of Evodia rutaecarpa for hypertension treatment obtained in step (3) were imported into the online tool STRING (https: / / string-db.org), and then "Homo sapiens" was selected, the minimum required interaction score was set to a high value ≥ 0.9, the idle nodes were hidden, and the number of kmeans clusters was selected as 3 in Cluster Option to obtain the PPI network. After the PPI network was established, the corresponding file was exported. The file was uploaded to Cytoscape3.9.1 software for further analysis. In Cytoscape3.9.1, the cytoNCA plug-in can screen the core targets for topological analysis.
[0052] The PPI network of 292 target genes of Evodia rutaecarpa in treating hypertension was constructed using STRING (see Figure 3 ), Figure 3 The number of edges is 767, the number of points is 292, and the average number of nodes is 5.25. The STRING exported file was imported into Cytoscape 3.9.1 to screen core targets, and the cytoNCA plug-in was used to analyze the PPI network. After that, we selected the top 10 targets with the highest degree that play a key role in the treatment of hypertension and drew a network diagram ( Figure 4 ), the larger the ring, the larger the connection score, and the degree, BC, and CC values are listed (Table 3).
[0053] Table 3 Topological parameters of core targets of Evodia rutaecarpa in treating hypertension
[0054]
[0055] (6) Gene Ontology (GO) functional enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis
[0056] To further demonstrate the role of Evodia rutaecarpa in treating hypertension, the DAVID database (https: / / david.ncifcrf.gov) was used to perform GO functional enrichment and KEGG enrichment analysis on the target genes of Evodia rutaecarpa in treating hypertension in terms of biological process (BP), cellular component (CC), and molecular function (MF). The 292 target genes of Evodia rutaecarpa in treating hypertension obtained in step (3) were imported into the database research preview, and the species was designated as "Homo sapiens". The exported results were visualized using the online mapping tool Microinformatics (http: / / www.bioinformatics.com.cn / ), and the "disease-pathway-target-component drug" network was constructed using Cytoscape3.9.1.
[0057] GO functional enrichment was performed on 292 target genes of Evodia rutaecarpa for the treatment of hypertension (one of which was an unknown gene), and a total of 1191 results were found, including 867 biological processes (BP), 104 cellular components (CC), and 220 molecular functions (MF). The top 20 results in biological processes, cellular components, and molecular functions were selected according to the P value to draw bubble charts (see Figure 5 , Figure 6 and Figure 7 ), the more red dots there are, the smaller the P value is and the higher the credibility is.
[0058] KEGG pathway enrichment analysis enriched 182 pathways in total, and 20 results were selected from the 182 pathways according to the P value to draw a bubble chart (see Figure 8 ), Figure 8 The pathways included calcium signaling pathway, cancer signaling pathway, sphingolipid signaling pathway, cAMP signaling pathway, etc. Based on the 20 results, the “disease-pathway-target-ingredient drug” network diagram was constructed using Cytoscape 3.9.1 software (see Fig. 9 ), there are 352 nodes and 1950 edges in the network, involving 1 traditional Chinese medicine, 1 disease, 20 pathways, 38 compounds and 292 genes.
[0059] (7) Docking analysis of bioactive compounds of Evodia rutaecarpa and potential antihypertensive targets
[0060] In the CGD network, the cytoNCAplugins tool in the Cytoscape3.9.1 software can screen out the five most important components according to the degree value. Then the PPI network is used to construct the network, and five critical gene targets are screened according to the size of the degree value. The core protein structures of the above five gene targets are obtained from the PDB online database (https: / / www.rcsb.org). After that, low-resolution X-ray structures, human structures, and structures of nucleotide binding sites binding ligands are preferred. At the same time, these five compounds need to be format converted so that they can be used in subsequent software. The SDF format of the 3D structure is obtained from the PubChem database and converted to MOL2 format using OpenBable2.4.1 software. PyMol2.5.0 software, installed by open source tools Python2.7, Miniconda3, Numpy1.19.5, and Pmw2.0.1, is often used to remove water and ligands and measure the distance between docked ligands and proteins. After that, AutoDock4 and AutoDockTool4 (https: / / autodock.scripps.edu) were used to dock the protein and ligand and calculate the binding energy. The exported files were in PDBQT format and needed to be converted to PDB format. They were then used in PyMol2.5.0 to measure distances and visualize the docking diagram of the protein and ligand. The binding site was constructed in PyMol2.5.0 software.
[0061] The top five main components were selected according to the degree value: 2-hexyloctan-1-ol, dihydroyashabushiketol, rutaecarpine, isorhamnetin, and ervodiamide. The proteins of SRC (PDB ID: 1YOM), MAPK3 (PDB ID: 2ZOQ), STAT3 (PDB ID: 6GFA), MAPK1 (PDB ID: ZZN), and PIK3R1 (PDB ID: 5AUL) were also selected according to the degree value. The binding energy of these proteins was calculated by mixing them one by one using AutoDock4 and AutoDockTool4 to obtain the binding energy data (see Table 4). The average binding energy was -1.044 kcal mol-1. The highest affinity was found for Evodiamide-PIK3R1, Isorhamnetin-PIK3R1, Rutaecarpine-MAPK3 and Rutaecarpine-PIK3R1. The highest affinity was -5.89, and most of them were negative. PyMol2.5.0 software was used to draw the molecular docking diagram and measure the distance between the protein and the ligand (see Fig.10 ) and draw a binding activity diagram (see Fig.11 ).
[0062] Table 4 Molecular docking binding energy data
[0063]
[0064] It should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solutions of the present invention may be modified or replaced by equivalents without departing from the spirit and scope of the technical solutions of the present invention, which should all be included in the scope of the claims of the present invention.
Claims
1. A method for analyzing the antihypertensive target of Evodia rutaecarpa based on network pharmacology, characterized in that: The steps include: S1. Screening of blood pressure-lowering bioactive ingredients of Evodia rutaecarpa: All chemical components of Evodia rutaecarpa were obtained from the HERB database and the TCMSP database. Based on the absorption, distribution, metabolism and excretion of pharmacological substances, the SwissADME database was used to screen the blood pressure-lowering bioactive ingredients of Evodia rutaecarpa from the HERB database, and the two standards of OB ≥ 30% and Druglikeness ≥ 0.18 were used to screen the blood pressure-lowering bioactive ingredients of Evodia rutaecarpa in the TCMSP database. S2. Collection of target genes of Evodia rutaecarpa for treating hypertension: Obtain the SMILES names corresponding to the blood pressure-lowering bioactive components of Evodia rutaecarpa screened from the HERB database and the TCMSP database in S1, and bring them into the SwissTargetPrediction database to obtain the target genes of Evodia rutaecarpa for treating hypertension; S3. Determine the target genes of Evodia rutaecarpa for treating hypertension based on the target genes of hypertension: Obtain the target genes of hypertension using the GeneCards database and the DisGeNET database, and draw a Venn diagram of the target genes of hypertension and the target genes of Evodia rutaecarpa for treating hypertension described in S2 using the online tool Venny 2.
1. The common genes are the target genes of Evodia rutaecarpa for treating hypertension. S4. Construction of compound-gene-disease network: Cytoscape3.9.1 software was used to generate a compound-gene-disease network diagram reflecting the relationship between the blood pressure-lowering bioactive components of Evodia rutaecarpa obtained in S1 and the target genes for treating hypertension of Evodia rutaecarpa obtained in S3; S5. Construct protein interaction network and extract core targets: Import the target genes of Evodia rutaecarpa for the treatment of hypertension obtained in S3 into the online tool STRING, then select "Homo sapiens", set the minimum required interaction score to a high value ≥ 0.9, hide idle nodes, and select the number of kmeans clusters as 3 in Cluster Option to obtain the protein interaction network and export the corresponding file. Upload the file to Cytoscape3.9.1 software and use the cytoNCA plug-in in the software to extract core targets.
2. The method according to claim 1, characterized in that S1 The method for screening the blood pressure-lowering bioactive ingredients of Evodia rutaecarpa from the HERB database is to screen the ingredients that meet the Lipinski five rules Mw≤500, miLogP≤5, nOHNH≤5, nOH≤10, the sum of the "Yes" numbers of Lipinsk, Ghose, Veber, Egan and Muegge is greater than 2, and the bioavailability is ≥30%, the oral bioavailability (OB) is ≥30%, and the GI absorption tendency is "high".
3. The method according to claim 1, characterized in that S2 The method of collecting target genes of Evodia rutaecarpa for treating hypertension from the HERB database is to use PubChem database to detect the blood pressure lowering bioactive component genes of Evodia rutaecarpa screened from the HERB database, find their SMILES names, and then bring them into SwissTargetPrediction database to obtain the target genes of Evodia rutaecarpa for treating hypertension.
4. The method according to claim 1, characterized in that: S2 The method of collecting target genes of Evodia rutaecarpa for treating hypertension from the TCMSP database is that the active ingredients in Evodia rutaecarpa with the effect of treating hypertension screened from the TCMSP database have SMILES names, and the SMILES names are directly brought into the SwissTargetPrediction database to obtain the target genes of Evodia rutaecarpa for treating hypertension.
5. A computer device, characterized in that: The method comprises a memory, a processor and a computer program stored in the memory and executable on the processor. When the processor executes the computer program, the method for analyzing the antihypertensive target of Evodia rutaecarpa based on network pharmacology as described in any one of claims 1 to 4 is implemented.
6. A computer-readable storage medium, characterized in that: The computer-readable storage medium stores a computer program, and when the computer program is executed by the processor, the method for analyzing the antihypertensive targets of Evodia rutaecarpa based on network pharmacology as described in any one of claims 1 to 4 is implemented.
Citation Information
Patent Citations
Method for analyzing liver cancer treatment target and molecular mechanism of radix scutellariae decoction based on network pharmacology and molecular docking
CN117153242A
Traditional Chinese medicine composition for treating cancer-related fatigue and preparation and application thereof
CN117838820A
